Pugashetti Janelle Vu, Khanna Dinesh, Kazerooni Ella A, Oldham Justin
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan.
Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan.
Rheum Dis Clin North Am. 2024 Aug;50(3):439-461. doi: 10.1016/j.rdc.2024.03.007.
Interstitial lung disease (ILD) complicates connective tissue disease (CTD) with variable incidence and is a leading cause of death in these patients. To improve CTD-ILD outcomes, early recognition and management of ILD is critical. Blood-based and radiologic biomarkers that assist in the diagnosis CTD-ILD have long been studied. Recent studies, including -omic investigations, have also begun to identify biomarkers that may help prognosticate such patients. This review provides an overview of clinically relevant biomarkers in patients with CTD-ILD, highlighting recent advances to assist in the diagnosis and prognostication of CTD-ILD.
间质性肺疾病（ILD）使结缔组织病（CTD）复杂化，发病率各异，是这些患者的主要死亡原因。为改善CTD-ILD的预后，ILD的早期识别和管理至关重要。长期以来，人们一直在研究有助于诊断CTD-ILD的血液和放射学生物标志物。包括组学研究在内的近期研究也已开始识别可能有助于预测此类患者预后的生物标志物。本综述概述了CTD-ILD患者临床相关的生物标志物，重点介绍了有助于CTD-ILD诊断和预后评估的最新进展。
